Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies? [0.03%]
MEK抑制剂作为未来癌症治疗药物的研发：我们从临床前和临床研究中学到了什么？
Iacopo Petrini,Giuseppe Giaccone
Iacopo Petrini
Introduction: The combination of MEK and BRAF inhibitors is effective in melanomas and other tumors with BRAF V600E mutations. MEK inhibitors enhance efficacy and delay the development of resistance to BRAF inhibitors. Re...
Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis [0.03%]
KL130008胶囊治疗类风湿性关节炎的药代动力学、药效学及耐受性 placebo对照试验
Yue Cheng,Xiaohong Zhu,Zhihui Liu et al.
Yue Cheng et al.
Background: KL130008, a novel selective JAK1/JAK2 inhibitor demonstrated acceptable safety and tolerability in Phase I studies involving healthy volunteers. This proof-of-concept trial aimed to characterize the pharmacoki...
Assessing the clinical development of zerlasiran, a small-interfering rna for elevated lipoprotein(a) [0.03%]
泽拉西单抗临床开发评估：一种治疗升高的血清脂蛋白(a)的小干扰RNA疗法
Xuan L Tang,Amanda J Hooper,John R Burnett
Xuan L Tang
Introduction: Lipoprotein(a) [Lp(a)] is an independent, inherited risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Lp(a) is composed of apoB-100 and apo(a). Lifestyle changes and statin ...
Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years? [0.03%]
癌症恶病质的实验性药物研发进展：过去五年中我们在临床上取得了哪些进步？
Maurizio Muscaritoli,Alessio Molfino,Simona Orlando et al.
Maurizio Muscaritoli et al.
Introduction: Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clin...
Assessing the clinical progress of Muvalaplin for lowering lipoprotein(a) [0.03%]
评估Muvalaplin降低Lp(a)的临床进展
Amanda J Hooper,P Mihika S Fernando,John R Burnett
Amanda J Hooper
Introduction: Lipoprotein(a) [Lp(a)] is an LDL-like particle, which is synthesized and assembled in the liver, and whose plasma levels are strongly associated with, and considered to be causative of, atherosclerotic cardi...
Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years? [0.03%]
弥漫性大B细胞淋巴瘤：过去五年里我们取得了哪些临床进展？
James Nolan,John Kuruvilla
James Nolan
Introduction: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma and has a rapidly evolving treatment landscape. For patients at increased risk of primary treatment failure and those with rel...
Glucagon‑Like Peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions [0.03%]
胰高血糖素样肽-1受体激动剂在多发性硬化症治疗中的前景、挑战和未来方向
Afsaneh Shirani,Olaf Stuve
Afsaneh Shirani
Introduction: This review evaluates the potential of glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) - first developed for type 2 diabetes and later approved for chronic weight management - to be repurposed as neu...
Sodium channel modulation as a therapeutic strategy for chemotherapy-induced peripheral neurotoxicity [0.03%]
化疗诱导的外周神经毒性的钠通道调制治疗策略
Sara Di Girolamo,Giulia Terribile,Paola Alberti et al.
Sara Di Girolamo et al.
Introduction: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common and significant side effect of cancer treatment, triggered by exposure to widely used chemotherapeutic agents such as vinca alkaloids, taxanes...
Early phase development of PI3kinase inhibitors for anticancer therapies [0.03%]
磷脂酰肌醇激酶抑制剂的早期开发在癌症治疗中的作用
Carlo Caputo,Angela Lombardi,Margherita Vicario et al.
Carlo Caputo et al.
Introduction: The PI3K/Akt/mTOR pathway plays a crucial role in regulating cell proliferation, survival and metabolism. Its aberrant activation promotes tumor development and progression. The most common oncogenic feature...
Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study [0.03%]
MG-ZG122在健康受试者中的安全性和耐受性、药代动力学、免疫原性和药效学：一项随机、双盲、安慰剂对照、剂量递增的I期临床试验
Xuan Zhang,Lingqiao Zhu,Qian Zhang et al.
Xuan Zhang et al.
Background: This phase I study aimed to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of MG-ZG122, an anti-thymic stromal lymphopoietin mAb, in a healthy Chinese population. ...